Identification of LncRNA CASC7/ miR-26/ASPN/TGF-β/Smad Axis in Endometrial Cancer
Identification of LncRNA CASC7/ miR-26/ASPN/TGF-β/Smad Axis in Endometrial Cancer
Xiajun Zhang1, Jie Yang2, Wenjun Zhou1, Zhenshi Chen2, Weidong Wu3, Shaoru Zhang2 and Lihui Wang2*
ABSTRACT
Endometrial cancer is the most common gynecological malignant tumor in many countries. TGF-β regulates cell proliferation, angiogenesis and metastasis, and is an inducer of epithelial-mesenchymal transformation. Tumor cells activate the TGF-β/Smad pathway, and inhibiting its signal transduction pathway is an important strategy for tumor therapy. First, we have found lncRNA CASC7 is a poor prognostic marker of endometrial cancer. Then, ASPN was specifically expressed in endometrium and cell specific expression in basophils, among the most similar genes, we found TGF-β3. Moreover, lncRNA CASC7 acts on miR-26, and miR-26 was predicted to regulate ASPN. Next, Except for SMAD2 and XIAP, the expression of ASPN, TGF-β1, TGF-β2, TGF-β3, SMAD3 and SMAD4 genes in normal tissues was higher than that in tumor tissues. ASPN was positively correlated with TGF-β1, TGF-β2, TGF-β3, SMAD3 and SMAD4. Pathway activity shows ASPN and TGF-β1 and TGF-β3 activate EMT. Finally, we speculate that lncRNA CASC7 inhibited miR-26, inhibited ASPN, inhibited TGF-β, and promoted XIAP, to activate SMAD/XIAP pathway, improving the survival rate and invasiveness of endometrial cancer cells. Collectively, this is the first time to describe the mechanism of lncRNA CASC7/miR-26/ASPN/TGF-β/Smad axis in the proliferation and invasion of endometrial cancer cells.
To share on other social networks, click on any share button. What are these?
